Safety and Efficacy of Marqibo in Metastatic Malignant Uveal Melanoma

Inclusion Criteria:

Uveal melanoma with histologic or cytologic confirmation of metastatic disease.
One unidimensionally measurable lesion. If this is a cutaneous lesion it must be at least 10 mm by caliper measure. If it is a visceral or nodal or soft tissue lesion, it must be >20 mm with conventional techniques or >10 mm with spiral CT scan. Bone lesions are not considered measurable.
Must not have received any prior systemic chemotherapy, immunotherapy, vaccine or hepatic arterial chemotherapy for metastatic disease.
Adequate liver, renal, and bone marrow function.
Zubrod performance status of 0-2.
Sign an informed consent form.

Exclusion Criteria:

Major surgery within 4 weeks of enrollment.
Advanced symptomatic central nervous system (CNS) involvement by melanoma and those on phenytoin or requiring steroids for brain metastases, spinal cord compression, or meningeal "carcinomatosis".
History of neurological disorders unrelated to chemotherapy (including familial neurological diseases and acquired demyelinating disorders).
Grade 2 or greater sensory, motor and/or autonomic neuropathy at screening from any cause.
Receiving treatment with drugs known to inhibit or induce hepatic drug metabolism by cytochrome P450-3A4 isoenzymes and/or P-glycoprotein within 1 week of study enrollment.